HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer

Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers,...

Full description

Bibliographic Details
Main Authors: Kitchen, Mark O., Bryan, Richard T., Emes, Richard D., Luscombe, Christopher J., Cheng, K.K., Zeegers, Maurice P., James, Nicholas D., Gommersall, Lyndon M., Fryer, Anthony A.
Format: Article
Published: Libertas Academica 2018
Subjects:
Online Access:https://eprints.nottingham.ac.uk/51274/
_version_ 1848798457313099776
author Kitchen, Mark O.
Bryan, Richard T.
Emes, Richard D.
Luscombe, Christopher J.
Cheng, K.K.
Zeegers, Maurice P.
James, Nicholas D.
Gommersall, Lyndon M.
Fryer, Anthony A.
author_facet Kitchen, Mark O.
Bryan, Richard T.
Emes, Richard D.
Luscombe, Christopher J.
Cheng, K.K.
Zeegers, Maurice P.
James, Nicholas D.
Gommersall, Lyndon M.
Fryer, Anthony A.
author_sort Kitchen, Mark O.
building Nottingham Research Data Repository
collection Online Access
description Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. We therefore sought to identify novel DNA methylation markers of HR-NMIBC clinical outcomes that might predict tumour behaviour at initial diagnosis and help guide patient management. Patients and methods: A total of 21 primary initial diagnosis HR-NMIBC tumours were analysed by Illumina HumanMethylation450 BeadChip arrays and subsequently bisulphite Pyrosequencing. In all, 7 had not recurred at 1 year after resection and 14 had recurred and/or progressed despite intra-vesical BCG. A further independent cohort of 32 HR-NMIBC tumours (17 no recurrence and 15 recurrence and/ or progression despite BCG) were also assessed by bisulphite Pyrosequencing. Results: Array analyses identified 206 CpG loci that segregated non-recurrent HR-NMIBC tumours from clinically more aggressive recurrence/progression tumours. Hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HRNMIBC recurrence and/or progression within 1 year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative predictive values. Conclusions: This is the first genome-wide DNA methylation analysis of a unique HR-NMIBC tumour cohort encompassing known 1-year clinical outcomes. Our analyses identified potential novel epigenetic markers that could help guide individual patient management in this clinically unpredictable disease
first_indexed 2025-11-14T20:20:04Z
format Article
id nottingham-51274
institution University of Nottingham Malaysia Campus
institution_category Local University
last_indexed 2025-11-14T20:20:04Z
publishDate 2018
publisher Libertas Academica
recordtype eprints
repository_type Digital Repository
spelling nottingham-512742020-05-04T19:26:07Z https://eprints.nottingham.ac.uk/51274/ HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer Kitchen, Mark O. Bryan, Richard T. Emes, Richard D. Luscombe, Christopher J. Cheng, K.K. Zeegers, Maurice P. James, Nicholas D. Gommersall, Lyndon M. Fryer, Anthony A. Background: High-risk non-muscle invasive bladder cancer (HR-NMIBC) is a clinically unpredictable disease. Despite clinical risk estimation tools, many patients are undertreated with intra-vesical therapies alone, whereas others may be over-treated with early radical surgery. Molecular biomarkers, particularly DNA methylation, have been reported as predictive of tumour/patient outcomes in numerous solid organ and haematologic malignancies; however, there are few reports in HR-NMIBC and none using genome-wide array assessment. We therefore sought to identify novel DNA methylation markers of HR-NMIBC clinical outcomes that might predict tumour behaviour at initial diagnosis and help guide patient management. Patients and methods: A total of 21 primary initial diagnosis HR-NMIBC tumours were analysed by Illumina HumanMethylation450 BeadChip arrays and subsequently bisulphite Pyrosequencing. In all, 7 had not recurred at 1 year after resection and 14 had recurred and/or progressed despite intra-vesical BCG. A further independent cohort of 32 HR-NMIBC tumours (17 no recurrence and 15 recurrence and/ or progression despite BCG) were also assessed by bisulphite Pyrosequencing. Results: Array analyses identified 206 CpG loci that segregated non-recurrent HR-NMIBC tumours from clinically more aggressive recurrence/progression tumours. Hypermethylation of CpG cg11850659 and hypomethylation of CpG cg01149192 in combination predicted HRNMIBC recurrence and/or progression within 1 year of diagnosis with 83% sensitivity, 79% specificity, and 83% positive and 79% negative predictive values. Conclusions: This is the first genome-wide DNA methylation analysis of a unique HR-NMIBC tumour cohort encompassing known 1-year clinical outcomes. Our analyses identified potential novel epigenetic markers that could help guide individual patient management in this clinically unpredictable disease Libertas Academica 2018-01-08 Article PeerReviewed Kitchen, Mark O., Bryan, Richard T., Emes, Richard D., Luscombe, Christopher J., Cheng, K.K., Zeegers, Maurice P., James, Nicholas D., Gommersall, Lyndon M. and Fryer, Anthony A. (2018) HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer. Biomarkers in Cancer . ISSN 1179-299X high-risk non-muscle invasive bladder cancer epigenetics methylation HumanMethylation450 BeadChip array prognostic biomarker http://journals.sagepub.com/doi/10.1177/1179299X17751920 doi:0.1177/1179299X17751920 doi:0.1177/1179299X17751920
spellingShingle high-risk non-muscle invasive bladder cancer
epigenetics
methylation
HumanMethylation450 BeadChip array
prognostic biomarker
Kitchen, Mark O.
Bryan, Richard T.
Emes, Richard D.
Luscombe, Christopher J.
Cheng, K.K.
Zeegers, Maurice P.
James, Nicholas D.
Gommersall, Lyndon M.
Fryer, Anthony A.
HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title_full HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title_fullStr HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title_full_unstemmed HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title_short HumanMethylation450K array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle Invasive bladder cancer
title_sort humanmethylation450k array–identified biomarkers predict tumour recurrence/progression at initial diagnosis of high-risk non-muscle invasive bladder cancer
topic high-risk non-muscle invasive bladder cancer
epigenetics
methylation
HumanMethylation450 BeadChip array
prognostic biomarker
url https://eprints.nottingham.ac.uk/51274/
https://eprints.nottingham.ac.uk/51274/
https://eprints.nottingham.ac.uk/51274/